Heron Therapeutics (HRTX) FCF Margin (2016 - 2025)
Historic FCF Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 3.48%.
- Heron Therapeutics' FCF Margin fell 54800.0% to 3.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.08%, marking a year-over-year decrease of 135600.0%. This contributed to the annual value of 16.8% for FY2024, which is 306900.0% up from last year.
- Per Heron Therapeutics' latest filing, its FCF Margin stood at 3.48% for Q3 2025, which was down 54800.0% from 29.77% recorded in Q2 2025.
- Heron Therapeutics' FCF Margin's 5-year high stood at 8.96% during Q3 2024, with a 5-year trough of 282.08% in Q2 2021.
- In the last 5 years, Heron Therapeutics' FCF Margin had a median value of 84.84% in 2023 and averaged 95.86%.
- In the last 5 years, Heron Therapeutics' FCF Margin crashed by -722000bps in 2021 and then soared by 1782200bps in 2022.
- Heron Therapeutics' FCF Margin (Quarter) stood at 221.0% in 2021, then surged by 43bps to 126.38% in 2022, then skyrocketed by 105bps to 6.44% in 2023, then plummeted by -573bps to 30.45% in 2024, then soared by 111bps to 3.48% in 2025.
- Its last three reported values are 3.48% in Q3 2025, 29.77% for Q2 2025, and 23.08% during Q1 2025.